Blood Tests for Differentiating Uterine Sarcoma from Benign Masses
The most useful blood test for distinguishing uterine sarcoma from benign uterine masses is the neutrophil-to-lymphocyte ratio (NLR), with a cut-off value of ≥2.12 providing 74.5% sensitivity and 70.3% specificity, which outperforms serum CA-125 testing. 1
Primary Laboratory Tests
Neutrophil-to-Lymphocyte Ratio (NLR)
- NLR ≥2.12 is the most powerful blood-based predictor for preoperative diagnosis of uterine sarcoma, demonstrating superior performance compared to CA-125 (sensitivity 74.5% vs. 52.3%, specificity 70.3% vs. 50.5%, accuracy 60.6% vs. 49.6%) 1
- A 2024 meta-analysis confirmed that patients with uterine sarcoma have significantly higher NLR levels compared to those with uterine myoma (pooled sensitivity 68%, specificity 64%) 2
- NLR also reflects disease recurrence and progression more accurately than CA-125 in patients with confirmed uterine sarcomas 1
Serum Lactate Dehydrogenase (LDH)
- Elevated serum LDH is a significant independent predictor of uterine sarcoma on multivariable analysis 3
- LDH is incorporated into validated preoperative diagnostic scoring systems (PRESS and rPRESS) with 2-point weighting due to its predictive value 3, 4
CA-125
- CA-125 has limited utility for distinguishing sarcoma from benign masses, with poor sensitivity (52.3%) and specificity (50.5%) 1
- One study found no significant predictive value for CA-125 in differentiating myoma from uterine sarcoma in the preoperative setting 5
- The NCCN guidelines suggest CA-125 may be helpful for monitoring clinical response in patients with extrauterine disease, not for initial diagnosis 6
Standard Initial Laboratory Panel
Essential Tests
- Complete blood count (CBC) with platelets is recommended for all patients with suspected uterine neoplasms to assess for anemia and assist with preoperative planning 6
- Liver function tests (LFTs), renal function tests, or chemistry profile should be obtained, particularly in patients ≥55 years with comorbidities 6
Integrated Diagnostic Scoring System
The revised PREoperative Sarcoma Score (rPRESS) combines multiple factors with the following point allocation (maximum 10 points):
- Age: 2 points (if predictive threshold met) 3, 4
- Serum LDH: 2 points (if elevated) 3, 4
- Endometrial cytology findings: 2 points (if positive) 3, 4
- MRI findings: 1 point (if suspicious) 3, 4
A cut-off score of ≥4 points provides 93.7% accuracy, 92.3% positive predictive value, and 94.0% negative predictive value for diagnosing uterine sarcoma 4
Important Caveats
- No single blood test definitively diagnoses uterine sarcoma—tissue diagnosis remains the gold standard 7
- Blood tests should be interpreted alongside imaging (preferably MRI) and clinical findings 6, 3
- Genetic testing should be considered for patients <50 years or those with significant family history of endometrial/colorectal cancer, as approximately 5% of endometrial cancers are hereditary 6
- The rarity of uterine sarcomas (only 3% of all uterine neoplasms) means that positive predictive values remain modest even with optimal testing 7